A Phase 3 interventional study of Lenvatinib and Sorafenib in Hepatocellular Carcinoma (HCC), sponsored by Eisai Limited. Completed at 188 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-05.
Sponsored by Eisai Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.
Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one has the largest enrollment, is the only one that started in 2013, is one of 13 in phase 3, and was the 2nd registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
First Hospital of China Medical University · Sites in China
Ages 18–80
National Cancer Center, Korea · Sites in Korea, Republic of
Ages 19–79
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 79 · Phase 3 17 · Phase 4 5
First in 2009; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 954 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 48 across the 121 interventional studies. Of the 21 that completed or were terminated, 6 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 121 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Limited, one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Limited is the lead sponsor of 48 studies on the registry; 2 are open to participants now.
20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd.: none open now, 4 under way, none of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 20 studies in Carcinoma, Hepatocellular by Eisai Co., Ltd., this one has the largest enrollment of the 14 interventional ones that give a count, is the only one that started in 2013, is the only one in phase 3, and was the 4th registered.
Eisai Co., Ltd.’s Carcinoma, Hepatocellular studies by the year they started, since 2004.
14 of the studies testing lenvatinib in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06041477Phase 3Sun Yat-sen UniversityConcurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC | 2027-07 |
| NCT05621499Tianjin Medical University Cancer Institute and HospitalHAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma | 2026-11 |
| NCT07081633AstraZenecaDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | 2026-11-30 |
| NCT04615143Sun Yat-sen UniversityTislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC | 2026-12-01 |
| NCT06524466Sun Yat-sen UniversityNeoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma | 2026-12-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, from their registry updates:
Among Eisai Co., Ltd.’s 20 in Carcinoma, Hepatocellular:
This tab as a report to print or save as PDF → With an account.
E7080-G000-304 is a multicenter, randomized, open-label, noninferiority Phase 3 study to compare the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment in participants with unresectable Hepatocellular Carcinoma (HCC).
Participants must have confirmed diagnosis of unresectable HCC with any of the following criteria:
At least one measurable target lesion according to modified () meeting the following criteria:
The lesion is suitable for repeat measurement.
Adequate bone marrow function, defined as:
Adequate liver function, defined as:
Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of 25 International Units Per Liter (IU/L) or equivalent units of BhCG).
A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
Exclusion Criteria
Imaging findings for HCC corresponding to any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Drug: Lenvatinib
Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Drug: Sorafenib
12 mg (or 8 mg) once daily (QD) oral dosing.
Also known as: E7080, Lenvima
400 mg twice daily (BID) oral dosing.
Overall Survival (OS)
OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.
Time frame: From date of randomization until date of death from any cause (approximately up to 3.8 years)
Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first. Disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
Time frame: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
Time to Progression (TTP)
TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
Time frame: The time from the date of randomization to the date of first documentation of disease progression (approximately up to 3.8 years)
Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
Time frame: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
The EORTC QLQ-C30 included 30 questions comprising 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social) and 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation, diarrhea and financial difficulties) and a single global health and QOL status score. Most questions used a 4-point scale (1=Not at all to 4=Very much); 2 questions used a 7-point scale (1= Very poor to 7=Excellent). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
Time frame: Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
Time to Clinically Meaningful Worsening of HRQoL Assessed Using - EORTC QLQ- Hepatocellular Carcinoma Domain (HCC 18)
The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. Each individual item ranges from 1 to 4, where 1 = "not at all" and 4 = "very much." All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represented a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represented a high QoL, but a high score for a symptom scale/item represented a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
Time frame: Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
Time to Clinically Meaningful Worsening of HRQoL Assessed Using EuroQol Five Dimension Health Questionnaire (EQ-5D-3L)
The EuroQol five dimension health questionnaire (EQ-5D-3L) assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
Time frame: Baseline up to Off-Treatment Visit (approximately up to 3.8 years)
Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib
AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 1 and Cycle 1 Day 15. Summarized data for all time points was reported. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
Time frame: Cycle 1 Day 1, Cycle 2 Day 1: pre-dose, 0.5-4 and 6-10 hours post-dose; Cycle 1 Day 15: pre-dose, 2-12 hours post-dose (cycle length= 28 days)
Disease Control Rate (DCR)
DCR was defined as the percentage of participants with a best overall response of CR or PR, or stable disease (SD). Best overall response of SD must have been \>=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target lesions. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.
Time frame: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
Clinical Benefit Rate (CBR)
CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD \>=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.
Time frame: From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)
Percent Change From Baseline in Serum Biomarker
The serum biomarkers analysed were angiopoietin-2 (ANG2), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), fibroblast growth factor 23 (FGF23) and vascular endothelial growth factor (VEGF) as blood serum biomarkers, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a blood tumor marker in serum. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.
Time frame: Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and at the Off-Treatment Visit (approximately up to 3.8 years)
Participants took part in the study at 154 investigative sites in Australia, Belgium, Canada, China, France, Germany, Hong Kong, Israel, Italy, Japan, South Korea, Malaysia, Philippines, Poland, Russia, Singapore, Spain, Taiwan, Thailand, United Kingdom, and the United States from 1 March 2013 to 10 March 2021.
| Milestone | Lenvatinib | Sorafenib |
|---|---|---|
| Started | 478 | 476 |
| Treated | 476 | 475 |
| Completed | 0 | 0 |
| Not completed | 478 | 476 |
| Withdrew: Death | 415 | 402 |
| Withdrew: Lost to follow-up | 8 | 12 |
| Withdrew: Withdrawal by subject | 14 | 10 |
| Withdrew: Sponsor decision | 41 | 52 |
OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.
| months | Lenvatinib | Sorafenib |
|---|---|---|
| Overall Survival (OS) | 13.6 ± 12.1 | 12.3 ± 10.4 |
PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first. Disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
| months | Lenvatinib | Sorafenib |
|---|---|---|
| Progression Free Survival (PFS) | 7.4 ± 6.9 | 3.7 ± 3.6 |
TTP was defined as the time from the date of randomization to the date of first documentation of disease progression based on mRECIST. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
| months | Lenvatinib | Sorafenib |
|---|---|---|
| Time to Progression (TTP) | 8.9 ± 7.4 | 3.7 ± 3.6 |
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) based on mRECIST. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference to the baseline sum of the diameters of target lesions. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
| percentage of participants | Lenvatinib | Sorafenib |
|---|---|---|
| Objective Response Rate (ORR) | 24.1 ± 20.2 | 9.2 ± 6.6 |
The EORTC QLQ-C30 included 30 questions comprising 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social) and 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnoea, appetite loss, insomnia, constipation, diarrhea and financial difficulties) and a single global health and QOL status score. Most questions used a 4-point scale (1=Not at all to 4=Very much); 2 questions used a 7-point scale (1= Very poor to 7=Excellent). All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
| months | Lenvatinib | Sorafenib |
|---|---|---|
| Time to Clinically Meaningful Worsening of Health Related Quality of Life (HRQoL) Assessed Using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | 1.7 ± 1.05 | 1.8 ± 1.05 |
The EORTC QLQ-HCC-18 was an 18-item questionnaire design used along with the 30-item EORTC QLQ-C30. EORTC QLQ-HCC 18 questionnaire included 8 symptom scales such as fatigue, jaundice, body image, nutrition, pain, fever, sex life and abdominal swelling. Each individual item ranges from 1 to 4, where 1 = "not at all" and 4 = "very much." All domain scores were calculated as an average of item scores and transformed to 0 to 100 score range. A high score for a functional scale represented a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represented a high QoL, but a high score for a symptom scale/item represented a high level of symptomatology/problem. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
| months | Lenvatinib | Sorafenib |
|---|---|---|
| Fatigue | 1.9 ± 1.81 | 1.8 ± 1.74 |
| Jaundice | 4.6 ± 3.72 | 3.7 ± 2.86 |
| Body Image | 2.8 ± 2.73 | 1.9 ± 1.84 |
| Nutrition | 4.1 ± 3.68 | 2.8 ± 2.04 |
| Pain | 2.7 ± 1.97 | 2.8 ± 2.73 |
| Fever | 5.5 ± 4.57 | 3.7 ± 2.99 |
| Sex Life | 7.4 ± 5.46 | 6.7 ± 4.60 |
| Abdominal swelling | 7.4 ± 5.52 | 7.4 ± 5.46 |
The EuroQol five dimension health questionnaire (EQ-5D-3L) assesses quality of life along 5 dimensions. Participants rate 5 aspects of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) by choosing from 3 answering options (1=no problems; 2=some problems; 3=extreme problems). The summed score ranges from 3-15 with "3" corresponding to no problems and "15" corresponding to severe problems in the 5 dimensions. EQ-5D-3L also included an EQ visual analogue scale (VAS) that ranges between 100 (best imaginable health) and 0 (worst imaginable health). Decrease from baseline in EQ-5D-3L signifies improvement. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best). EQ-5D-3L also included an EQ health utilities index (HUI) where 1.00 indicated perfect health while a score of 0.00 indicated death. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
| months | Lenvatinib | Sorafenib |
|---|---|---|
| VAS | 2.8 ± 2.17 | 1.9 ± 1.84 |
| HUI | 2.8 ± 1.97 | 1.9 ± 1.84 |
AUC was assessed on Cycle 1 Day 1, Cycle 2 Day 1 and Cycle 1 Day 15. Summarized data for all time points was reported. As planned, data for this secondary endpoint was collected and analyzed up to the primary completion date.
| nanogram*hour per milliliter (ng*h/mL) | Lenvatinib 8 mg | Lenvatinib 12 mg |
|---|---|---|
| Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib | 1969.6 ± 743.0 | 2120.9 ± 685.6 |
DCR was defined as the percentage of participants with a best overall response of CR or PR, or stable disease (SD). Best overall response of SD must have been \>=7 weeks after randomization. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD and was new non-target lesions. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.
| percentage of participants | Lenvatinib | Sorafenib |
|---|---|---|
| Disease Control Rate (DCR) | 75.5 ± 71.7 | 60.5 ± 56.1 |
CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD \>=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.
| percentage of participants | Lenvatinib | Sorafenib |
|---|---|---|
| Clinical Benefit Rate (CBR) | 59.0 ± 54.6 | 38.4 ± 34.1 |
The serum biomarkers analysed were angiopoietin-2 (ANG2), fibroblast growth factor 19 (FGF19), fibroblast growth factor 21 (FGF21), fibroblast growth factor 23 (FGF23) and vascular endothelial growth factor (VEGF) as blood serum biomarkers, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) as a blood tumor marker in serum. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.
| percent change | Lenvatinib | Sorafenib |
|---|---|---|
| ANG 2: Cycle 1 Day 15 | -28.1 ± 15.94 | 8.9 ± 23.96 |
| ANG 2: Cycle 2 Day 1 | -28.8 ± 16.53 | -0.9 ± 24.06 |
| ANG 2: Cycle 3 Day 1 | -32.2 ± 23.23 | 0.5 ± 26.62 |
| ANG 2: Cycle 4 Day 1 | -35.6 ± 22.91 | -4.5 ± 20.05 |
| ANG 2: Cycle 5 Day 1 | -38.9 ± 19.83 | 7.0 ± 23.25 |
| ANG 2: Cycle 6 Day 1 | -36.7 ± 23.59 | -3.6 ± 24.82 |
| ANG 2: Cycle 7 Day 1 | -41.4 ± 21.20 | 1.0 ± 32.83 |
| ANG 2: Cycle 8 Day 1 | -40.2 ± 25.33 | -6.7 ± 31.26 |
| ANG 2: Cycle 9 Day 1 | -39.6 ± 14.04 | -1.1 ± 29.68 |
| ANG 2: Off-Treatment | 11.7 ± 99.13 | 16.8 ± 27.88 |
| FGF19: Cycle 1 Day 15 | 75.0 ± 155.01 | 1.3 ± 83.65 |
| FGF19: Cycle 2 Day 1 | 66.5 ± 134.26 | 36.6 ± 119.65 |
| FGF19: Cycle 3 Day 1 | 86.9 ± 123.85 | 22.8 ± 70.58 |
| FGF19: Cycle 4 Day 1 | 208.1 ± 602.11 | 46.8 ± 214.14 |
| FGF19: Cycle 5 Day 1 | 152.8 ± 228.37 | -1.0 ± 40.36 |
| FGF19: Cycle 6 Day 1 | 119.8 ± 203.81 | 26.9 ± 67.13 |
| FGF19: Cycle 7 Day 1 | 64.4 ± 101.97 | -5.9 ± 57.39 |
| FGF19: Cycle 8 Day 1 | 95.8 ± 135.31 | 53.9 ± 113.79 |
| FGF19: Cycle 9 Day 1 | 159.3 ± 202.00 | 56.6 ± 109.46 |
| FGF19: Off-Treatment | 140.1 ± 270.73 | 9.0 ± 64.17 |
| FGF 21: Cycle 1 Day 15 | 22.0 ± 75.22 | 4.0 ± 43.14 |
| FGF 21: Cycle 2 Day 1 | 15.7 ± 77.44 | 18.6 ± 57.18 |
| FGF 21: Cycle 3 Day 1 | 38.3 ± 38.3 | 49.4 ± 76.43 |
| FGF 21: Cycle 4 Day 1 | 42.9 ± 145.43 | 32.8 ± 70.63 |
| FGF 21: Cycle 5 Day 1 | 41.0 ± 95.97 | 31.1 ± 43.15 |
| FGF 21: Cycle 6 Day 1 | 52.6 ± 168.22 | 23.2 ± 40.90 |
| FGF 21: Cycle 7 Day 1 | 63.4 ± 128.34 | 23.7 ± 53.84 |
| FGF 21 : Cycle 8 Day1 | 38.3 ± 115.53 | 17.0 ± 68.51 |
| FGF 21: Cycle 9 Day1 | 59.1 ± 108.39 | 68.9 ± 103.55 |
| FGF 21: Off-Treatment | 141.4 ± 340.51 | 104.9 ± 183.28 |
| FGF 23: Cycle 1 Day15 | 23.9 ± 49.01 | -16.3 ± 36.14 |
| FGF 23: Cycle 2 Day 1 | 20.9 ± 56.91 | -6.2 ± 48.18 |
| FGF 23: Cycle 3 Day 1 | 25.5 ± 45.27 | 17.3 ± 75.25 |
| FGF 23: Cycle 4 Day 1 | 29.5 ± 48.38 | 14.2 ± 49.29 |
| FGF 23: Cycle 5 Day 1 | 29.6 ± 63.69 | 1.0 ± 47.28 |
| FGF 23: Cycle 6 Day 1 | 26.3 ± 54.57 | -10.6 ± 46.15 |
| FGF 23: Cycle 7 Day 1 | 31.5 ± 57.44 | 0.7 ± 46.95 |
| FGF 23: Cycle 8 Day 1 | 38.1 ± 67.35 | 2.8 ± 43.84 |
| FGF 23: Cycle 9 Day 1 | 23.2 ± 62.58 | 0.5 ± 38.74 |
| FGF 23: Off-Treatment | 17.8 ± 73.59 | 14.2 ± 47.11 |
| PIVKA-II: Cycle 1 Day 15 | 80.0 ± 171.41 | 166.9 ± 256.04 |
| PIVKA-II: Cycle 2 Day 1 | 169.7 ± 329.33 | 243.8 ± 416.82 |
| PIVKA-II: Cycle 3 Day 1 | 252.4 ± 611.40 | 218.7 ± 281.45 |
| PIVKA-II: Cycle 4 Day 1 | 371.7 ± 812.45 | 196.2 ± 348.80 |
| PIVKA-II: Cycle 5 Day 1 | 628.2 ± 1752.64 | 369.5 ± 766.59 |
| PIVKA-II: Cycle 6 Day 1 | 648.7 ± 2746.41 | 415.7 ± 554.27 |
| PIVKA-II: Cycle 7 Day 1 | 184.8 ± 352.75 | 703.6 ± 1226.58 |
| PIVKA-II: Cycle 8 Day 1 | 277.8 ± 481.53 | 724.0 ± 1257.87 |
| PIVKA-II: Cycle 9 Day 1 | 318.8 ± 577.21 | 859.1 ± 1492.93 |
| PIVKA-II: Off-Treatment | 809.3 ± 1827.42 | 272.5 ± 489.60 |
| VEGF: Cycle 1 Day 15 | 157.5 ± 300.21 | 97.4 ± 118.43 |
| VEGF: Cycle 2 Day 1 | 128.9 ± 333.85 | 94.0 ± 180.80 |
| VEGF: Cycle 3 Day 1 | 97.7 ± 162.39 | 66.0 ± 124.58 |
| VEGF: Cycle 4 Day 1 | 113.4 ± 231.19 | 76.1 ± 111.20 |
| VEGF: Cycle 5 Day 1 | 132.4 ± 249.59 | 116.2 ± 215.57 |
| VEGF: Cycle 6 Day 1 | 113.1 ± 219.36 | 130.9 ± 341.12 |
| VEGF: Cycle 7 Day 1 | 133.1 ± 383.43 | 96.9 ± 173.77 |
| VEGF: Cycle 8 Day 1 | 148.7 ± 349.58 | 181.1 ± 399.67 |
| VEGF: Cycle 9 Day 1 | 129.6 ± 215.05 | 135.6 ± 267.61 |
| VEGF: Off-Treatment | 127.1 ± 266.64 | 147.8 ± 304.31 |
Collected over All treatment-emergent adverse events were collected from first dose of study drug (Baseline) up to 30 days after last dose of study drug (approximately up to 8 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenvatinib | 415/478 (86.8%) | 209/476 (43.9%) | 469/476 (98.5%) |
| Sorafenib | 402/476 (84.5%) | 149/475 (31.4%) | 469/475 (98.7%) |
| Event | Lenvatinib | Sorafenib |
|---|---|---|
| Hepatic encephalopathyNervous system disorders | 21/476 | 3/475 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 11/476 | 14/475 |
| Hepatic failureHepatobiliary disorders | 14/476 | 8/475 |
| AscitesGastrointestinal disorders | 12/476 | 12/475 |
| Abdominal painGastrointestinal disorders | 6/476 | 11/475 |
| Decreased appetiteMetabolism and nutrition disorders | 11/476 | 2/475 |
| DiarrhoeaGastrointestinal disorders | 8/476 | 2/475 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 7/476 | 5/475 |
| Jaundice cholestaticHepatobiliary disorders | 7/476 | 4/475 |
| Blood bilirubin increasedInvestigations | 7/476 | 1/475 |
| Event | Lenvatinib | Sorafenib |
|---|---|---|
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 128/476 | 246/475 |
| DiarrhoeaGastrointestinal disorders | 186/476 | 223/475 |
| HypertensionVascular disorders | 200/476 | 147/475 |
| Decreased appetiteMetabolism and nutrition disorders | 162/476 | 126/475 |
| Weight decreasedInvestigations | 149/476 | 108/475 |
| FatigueGeneral disorders | 141/476 | 120/475 |
| AlopeciaSkin and subcutaneous tissue disorders | 15/476 | 120/475 |
| ProteinuriaRenal and urinary disorders | 117/476 | 55/475 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 113/476 | 57/475 |
| NauseaGastrointestinal disorders | 90/476 | 71/475 |
The full analysis set (FAS) included all participants who were randomized.
| Age, Continuous(years) | Lenvatinib | Sorafenib | Total |
|---|---|---|---|
| Mean | 61.3 ± 11.69 | 61.2 ± 12.01 | 61.3 ± 11.84 |
| Sex: Female, Male(Participants) | Lenvatinib | Sorafenib | Total |
|---|---|---|---|
| Female | 73 | 75 | 148 |
| Male | 405 | 401 | 806 |
| Ethnicity (NIH/OMB)(Participants) | Lenvatinib | Sorafenib | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 11 | 17 |
| Not Hispanic or Latino | 472 | 465 | 937 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Lenvatinib | Sorafenib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 334 | 326 | 660 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 7 | 6 | 13 |
| White | 135 | 141 | 276 |
| Other | 1 | 2 | 3 |
Showing the first 100 of 188 sites across 21 countries. Choose a country and city above to see the rest.
Ran from Mar 2013 to primary completion in Nov 2016, 44 months.
Results were first posted in Sep 2018, 1 year 10 months after primary completion. A results delay was requested in Jan 2018.
Of 53 industry-sponsored phase 3 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 63. This study's 44 months is below that.
Counting every sponsor, half of 139 studies reached it within 56 months; a quarter within 43 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib